A Phase 1, Open-label, Dose-escalation, Safety and Biomarker Prediction of Alvocidib and Cytarabine/Daunorubicin (7+3) in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
Latest Information Update: 18 Oct 2023
At a glance
- Drugs Alvocidib (Primary) ; Cytarabine (Primary) ; Daunorubicin (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; Biomarker
- Acronyms Zella 101
- Sponsors Sumitomo Dainippon Pharma Oncology; Sumitomo Pharma America; Tolero Pharmaceuticals
- 30 Sep 2020 Results published in the Clinical Cancer Research
- 21 Jun 2020 Results presented at the 25th Congress of the European Haematology Association
- 12 Jun 2020 Results presented in a Tolero Pharmaceuticals media release.